We report a case of therapy-related secondary acute myeloid leukemia occurring in a patient during treatment for anaplastic large cell lymphoma. In spite of response to induction chemotherapy and prompt bone marrow transplantation from his matched sister, the patient experienced an early leukemia relapse within 3 months of the transplant. Treatment with oral etoposide for 3 weeks followed by donor lymphocyte infusion achieved a 7-month remission from leukemia without any further treatment. Unfortunately, the patient suffered a recurrence of the primary anaplastic large cell lymphoma that was treated by resuming chemotherapy and local radiotherapy. The patient died 20 months after DLI, still in CR for his leukemia, due to ALCL progression. Keywords: anaplastic large cell lymphoma; donor lymphocyte infusion; allogeneic bone marrow transplantation; immunotherapy Relapse of a hematological malignancy after allogeneic bone marrow transplantation (BMT) is often inadequately dealt with by conventional treatment.
1
In the past few years, several authors have reported that donor lymphocyte infusion (DLI) can induce stable remissions in patients with cytogenetic or hematological relapse of chronic myeloid leukemia after BMT. 2, 3 The efficacy of this approach has also been reported, though less frequently, in other malignancies. 2, 4 The rationale for this treatment is based on the anti-leukemic effect of allogeneic BMT, called graft-versus-leukemia (GVL), mediated by donor lymphocytes (T cells and natural killers cells). 5 To improve the outcome of DLI in acute leukemia, an increase in the number of infused cells could be explored, but at risk of severe toxicity since GVL effect is Correspondence: Dr S Cesaro, Clinica Onco-Ematologia Pediatrica, Dipartimento di Pediatria, Complesso Università-Azienda Ospedale di Padova, 35128 Padova, Italy Received 29 June 1998; accepted 10 October 1998 closely associated with GVHD. Cell-reducing chemotherapy has been used before DLI to reduce tumor burden and enhance the ratio of the donor allogeneic cells to the host leukemic cells.
We report a case of secondary AML (sAML) relapsing after matched related allogeneic BMT successfully treated with chemotherapy and DLI, although this treatment failed to prevent recurrence of the primary disease.
Case report
An anaplastic large cell lymphoma (ALCL) was diagnosed on bone biopsy in a 15-year-old male with bone pain (left shoulder and right leg) and osteolytic lesions (right anterior iliac spine and proximal left humerus). Immunological typing was CD30 + , T and B−. Cytogenetic analysis revealed the typical t(2;5) chromosomal translocation. Medical history revealed a family history of cancer: his father had been cured 9 year earlier of lymphoma and his grandfather had suffered from cancer of the testis and larynx.
Chemotherapy was administered according to the AIEOP (Italian Association of Pediatric Hematology-Oncology) NHL 92-ALCL protocol. After an LSA2-L2-like induction and consolidation courses (Table 1) , the patient was treated with maintenance phase I (weekly, alternating a couple of drugs) until completion of the 12 months of therapy, and maintenance phase II (weekly methotrexate and daily 6-mercaptopurin) for a total 24 months of therapy. 6 He obtained prompt relief from pain, followed by a reduction in the osteolytic lesions. At the end of consolidation treatment, he was considered to be in clinical remission with a clear improvement in the bone lesions on skeletal 99 Tc scan. Nineteen months after the diagnosis of ALCL, he complained of fatigue and a peripheral blood test disclosed a WBC of 85.6 × 10 9 /l with 95% monoblasts, hemoglobin 12.7 g/l, platelets 62 × 10 9 /l. Bone marrow aspirate confirmed an acute monoblastic leukemia (AML-M5a according to the FAB classification). Karyotyping showed the typical epipodophyllotoxin-related 11q23 rearrangement: 46,XY,t(9;11)(p21;q 23), by which time the boy had received a cumulative etoposide dose of 4 g (2.285 g/m 2 ) and a cumulative teniposide dose of 2.08 g (1.188 g/m 2 ). and low oral doses of etoposide (20 mg/day for 3 Chemotherapy suspended after 1 month on weeks a month) patient decision 3rd ALCL relapse 18.11 Palliative radiotherapy Died (lymph nodes, skin, muscles, bones) ALCL = anaplastic large cell lymphoma; CR = complete remission; DLI = donor lymphocyte infusion; TNC = total nucleated cells; CNC = central nervous system. a LSA 2 -L 2 like protocol consisting of induction (vincristine, cyclophosphamide, daunomycin, prednisone); consolidation (thioguanine, cytarabine, lasparaginase, methotrexate); maintenance I (weekly alternating pairs of drugs: cyclophosphamide-etoposide, methotrexate-6-mercaptopurine, cytarabineteniposide, and vincristine-dexamethasone) up to completion of the first year of therapy; maintenance II (daily oral 6-mercaptopurin and weekly methotrexate) up to completion of 24 months of therapy. He was treated according to the AIEOP AML protocol, based on two courses of idarubicin, etoposide and cytarabine for 2, 3 and 7 days, respectively. Hematological and cytogenetic remission was obtained after the first course and allogeneic bone marrow transplantation from his HLAmatched sister was scheduled. Although the bone marrow aspirate just before starting conditioning showed 13% blasts, the patient underwent BMT. The conditioning regimen consisted of BU 14 mg/kg, CY 120 mg/kg and melphalan 140 mg/m 2 . The total unmanipulated mononuclear cell dose was 2.3 × 10 8 /kg. CsA was administered for GVHD prophylaxis. Engraftment was rapid with ANC Ͼ0.5 × 10 9 /l on day 16 and platelets Ͼ50 × 10 9 /l on day 37. Bone marrow aspirate on day 43 demonstrated complete remission. A second aspirate performed on day 61 for an increasing lactate dehydrogenase level and concomitant drop in platelets showed a partial relapse of AML (33% monoblasts). At chimerism analysis, 50% of cells were of host origin.
Cell sorted FISH (fluorescence in situ hybridization) analysis confirmed reappearance of the malignant clone with 11q23 rearrangement. CsA was discontinued and the patient was discharged on oral etoposide. Bone marrow aspirate on day 95 showed a reduction of blasts to less than 5%, lactate dehydrogenase value within the normal range and 100% marrow cells of donor origin on chimerism analysis. Lymphocytes obtained from leukapheresis of his HLA-matched sister were administered on day 105 at a dose of 1.3 × 10 8 /kg. Acute skin (grade II-III), liver (grade III-IV) and gut (grade I) GVHD appeared on day 140, and oral CsA (8-12 mg/kg/day) was resumed, together with prednisone (2 mg/kg/day). Skin and gut, but not liver, GVHD improved with immunosuppressive therapy, so the patient started photopheresis from day 162. Liver GVHD had progressively improved from grade III-IV (total bilirubin level: 235-300 mmol/l) to grade I (total bilirubin level: 25-48 mmol/l; nv 1.7-17) by day 250, after nine courses of photopheresis, permitting the tapering of prednisone. Bone marrow aspirate performed at this stage showed complete remission of leukemia, and periodic chimerism analysis was always consistent with 100% blood and marrow cells of donor origin.
On day 272 the patient presented with retro-auricular and occipital lymphadenopathy associated with a VIIth nerve palsy. MRI revealed an intracranial lesion within the sphenoid sinus extending to the sellar region, of 3 × 2 cm in diameter, with enhancement after gadolinium. A skeletal 99 Tc scan showed an abnormal tibial and acromioclavicular joint. Retro-auricular lymph node biopsy demonstrated a relapse of ALCL. The patient received 2400 cCy fractionated cranial irradiation (with a boost of 1200 cCy to the central nervous area involved) and chemotherapy was resumed. Despite poor chemotherapy tolerance due to considerable myelotoxicity and fatigue, the patient achieved a CR lasting 6 months, when a new nodular skin lesion of the left foot associated with bone pain in the feet was noted. He was re-treated with 3600 cCy to the feet and began receiving a low oral dose of etoposide (20 mg/m 2 daily) for 3 weeks a month. He decided to suspend chemotherapy and remained symptom-free for 4 months until ALCL progression was diagnosed. New masses appeared in the abdomen (involving the retroperitoneal lymph nodes), the right leg and left upper arm, and laterocervical lymph nodes and multiple bone lesions in skeletal bones were noted. He died 20 months after DLI, still in CR for his leukemia, from renal and respiratory failure due to ALCL progression.
Discussion
Chemotherapy based on the use of epipodophyllotoxin or intercalating topoisomerase II inhibitors (doxorubicin, dactinomycin) combined with alkylating agents and irradiation have been correlated with the onset of sAML 7 in patients previously treated either for hematological malignancies or solid tumors. 8 Most of the characteristics of topoisomerase II therapy-related sAML were observed in our case, eg a short latency of onset (19 months), absence of any prior myelodysplastic phase, AML-M5 on FAB classification and chromosomal rearrangement at the break point 11q23.
The outcome of sAML is dismal due to high relapse rates, and treatment is based on prompt allogeneic bone marrow transplantation, with or without prior intensive chemotherapy. The disease-free survival rate is about 30%.
9,10 Hematological remission is desirable prior to marrow grafting, but prompt transplantation is equally important if the patient has a histocompatible familial donor. In our case, complete remission was documented with the first course of induction chemotherapy, but it was short-lived (2 months) and the bone marrow aspirate prior to starting conditioning therapy showed recurrent leukemia (13% of blasts). The management of sAML relapse after allogeneic stem cell transplantation is extremely difficult because intensive chemotherapy or repeated grafts are associated with a high mortality. Over the past few years, there have been several reports on the use of DLI as immunotherapy in patients relapsing after allogeneic BMT. The treatment is based on the observation that there is a strong correlation between GVHD and GVL. In fact, relapse rate is higher with syngenic BMT than allogeneic BMT and with T cell-depleted than non-T cell-depleted BMT. The GVHD-GVL effect is presumably mediated by donor leukocytes (T cells and natural killer cells). It has been reported that DLI can induce remission in 73-75% of CML patients with either cytogenetic-only or chronic phase relapse, whereas complete remission rates in AML and ALL are 15.4-29% and 0-18.2%, respectively. 2, 11 In these cases, DLI is probably unable to induce an adequate antileukemia effect because of rapid disease progression. Reducing tumor burden with chemotherapy before DLI could reproduce the same scenario as in cytogenetic or hematological chronic phase relapsed CML. In our patient, treatment with oral etoposide for 3 weeks resulted in morphological remission and re-established 100% donor chimerism. With subsequent DLI, the patient had a 6-month period of remission from leukemia without any further treatment. As already reported, the GVL effect was associated with severe GVHD, which was controlled by resuming immunosuppressive (steroid and cyclosporin) treatment and photoapheresis. Some approaches, such as selective CD8 + cell depletion or the reduction of at least a logarithm of the number of T cells infused, seem to have potential for reducing the incidence of GVHD. 12, 13 The mechanism of response to DLI is uncertain, but is probably mediated by those alloreactive T cells directed against minor histocompatibility antigens shared between normal and leukemic cells. Response to DLI is very often associated with the onset of GVHD, but in some cases has also been recorded in the absence of GVHD. This fact supports the theory that the GVL effect could be induced without any GVHD effect.
12,13 DLI has also been tested in other hematologic neoplasms with promising results, including multiple myeloma relapsing after allo-BMT. 4 Data on the efficacy of DLI for NHL are scanty but scattered reports are not encouraging. Collins et al 2 reported a series of six NHL patients relapsing after allo-BMT who did not benefit from DLI. Even in our case, the GVL effect of DLI did not prevent the primary ALCL from relapsing, despite persistent remission of sAML and complete donor type of the patient. We could speculate that lymphoma cells have a higher threshold of response to DLI, or are possibly totally unresponsive, so they can easily face and escape the immunological attack from the T cells. The possible explanation is the absence or decreased expression of cellsurface tumor antigens capable of triggering an immunological response.
14 A way to overcome this response, could be the infusion of higher doses of T cells, albeit at risk of severe, even lethal toxicity. Another promising approach could be the isolation and propagation in vitro of specific cytotoxic T lymphocytes capable of selectively identifying and eliminating tumor cells. Such an approach is currently being explored for prophylaxis and treatment of viral infection (Epstein-Barr virus, CMV) in bone marrow and solid organ transplants. 15, 16 
